NEW YORK (GenomeWeb) — Phosphorus announced today that it has received approval for its PhosphorusOne genetic test from the New York State Department of Health.
PhosphorusOne uses next-generation sequencing to analyze 375 genes covering 170 inherited conditions and 175 different drug reactions, and is designed to provide information on an individual's genetic health risk for a range of diseases including cancer, heart disease, and dementia. It also assesses predisposition to adverse reaction to drugs and therapeutics, as well as certain wellness traits.
"Historically, genetic tests to screen for disease have been limited to high-risk populations," Malgorzata Jaremko, senior vice president and laboratory director at Phosphorus, said in a statement. "By bringing down the cost of a holistic screen, the PhosphorusOne test provides the opportunity to maximize disease prevention and early detection amongst not just the high-risk, but the general population."
Earlier this year, New York City-based Phosphorus received a clinical laboratory permit and approval for its NGS-based tests for hereditary cancers and arrhythmias from the NYSDOH.